High B‐cell activating factor is not associated with worse 3‐year graft outcome in blood group‐incompatible kidney transplantation with rituximab induction

Publisher： John Wiley & Sons Inc

E-ISSN： 1399-0012|29|4|359-364

ISSN： 0902-0063

Source： CLINICAL TRANSPLANTATION (ELECTRONIC), Vol.29, Iss.4, 2015-04, pp. : 359-364

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

B‐cell activating factor, a predictor of antibody mediated rejection in kidney transplantation recipients

By  

NEPHROLOGY, Vol. 23, Iss. 2, 2018-02 ,pp. : 169-174

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of blood group antibodies in ABO‐incompatible living‐donor kidney transplantation

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 22, Iss. 10, 2015-10 ,pp. : 931-936

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of blood group antibodies in ABO‐incompatible living‐donor kidney transplantation

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 919-8172, Iss. 10, 2015-10 ,pp. : 931-936

John Wiley & Sons Inc

Access to resources Recommend Favorite

Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients

By Ruyssen-Witrand Adeline  

British Journal of Rheumatology , Vol. 52, Iss. 4, 2013-04 ,pp. : 636-641

Oxford University Press

Access to resources Recommend Favorite

B cell phenotype after rituximab in TTP patients

By  

CLINICAL & EXPERIMENTAL IMMUNOLOGY, Vol. 179, Iss. 3, 2015-03 ,pp. : 414-425

John Wiley & Sons Inc

Access to resources Recommend Favorite